Nuclear Stat5a/b predicts early recurrence and prostate cancer–specific death in patients treated by radical prostatectomy-Reference-Cited by-同舟云学术

Nuclear Stat5a/b predicts early recurrence and prostate cancer–specific death in patients treated by radical prostatectomy

Published:2013-03 Issue:3 Volume:44 Page:310-319
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Mirtti Tuomas,Leiby Benjamin E.,Abdulghani Junaid,Aaltonen Elina,Pavela Miia,Mamtani Anita,Alanen Kalle,Egevad Lars,Granfors Torvald,Josefsson Andreas,Stattin Par,Bergh Anders,Nevalainen Marja T.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference34 articles.

1. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

2. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy;D'Amico;J Natl Cancer Inst,2003

3. An update of the Gleason grading system;Epstein;J Urol,2010

4. 20-year outcomes following conservative management of clinically localized prostate cancer;Albertsen;JAMA,2005

5. Predicting 15-year prostate cancer specific mortality after radical prostatectomy;Eggener;J Urol,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling;Science Advances;2024-03

2. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics;Cancers;2024-01-24

3. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer;Signal Transduction and Targeted Therapy;2023-05-19

4. Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor;PLOS ONE;2022-11-14

5. Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19;Biomedicines;2022-10-19